{"nctId":"NCT02008318","briefTitle":"A Study of Galunisertib in Participants With Myelodysplastic Syndromes","startDateStruct":{"date":"2014-03"},"conditions":["Myelodysplastic Syndromes"],"count":43,"armGroups":[{"label":"Phase (ph) 2: Galunisertib + BSC","type":"EXPERIMENTAL","interventionNames":["Drug: Galunisertib"]},{"label":"Ph 3: Placebo + BSC","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Ph 3: Galunisertib + BSC","type":"EXPERIMENTAL","interventionNames":["Drug: Galunisertib"]}],"interventions":[{"name":"Galunisertib","otherNames":["LY2157299"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of MDS based on the World Health Organization (WHO) criteria\n* Participants with 5q deletions are allowed only if they have failed or are intolerant of lenalidomide treatment\n* Participants must have a Revised International Prognostic Scoring System (IPSS-R) category of very low-, low-, or intermediate-risk disease\n* In the 8 weeks prior to registration, participants in phase 2 should have anemia with Hb ≤10.0 g/dL (based on the average of 2 baseline measurements and untransfused for at least 1 week) with or without red blood cell (RBC) transfusion dependence confirmed for a minimum of 8 weeks before enrollment\n* For phase 3, participants should have anemia with RBC transfusion dependence confirmed within 8 weeks before enrollment\n* Performance status ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale\n\nExclusion Criteria:\n\n* No history of moderate or severe cardiac disease\n* No prior history of acute myeloid leukemia (AML)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Hematological Improvement (HI)","description":"Percentage of participants with hematological improvement (HI) based on International Working Group (IWG) 2006 criteria in participants with very low, low, and intermediate-risk myelodysplastic syndromes treated with Galunisertib plus best supportive care, as assessed by the International Prognostic Scoring System (IPSS-R).\n\nTo be classified as an HI responder, the HI response must have lasted at least 8 weeks (56 days).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Are Transfusion-free or Have Hemoglobin (Hb) Increase ≥1.5 Grams/Deciliter Maintained for 8 Weeks During Phase 3","description":"Comparison of the percentage of participants with very low-, low-,and intermediate-risk MDS who were transfusion-free or had an increase ≥1.5 g/dL in hemoglobin (Hb) maintained for at least 8 weeks within the first 24 weeks of treatment with galunisertib plus best supportive care or placebo plus best supportive care and assessed by IPSS-R.\n\nThe Phase 3 portion of this study was not conducted because efficacy level required in phase 2 to move forward to phase 3 was not achieved.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Brief Fatigue Inventory (BFI)","description":"The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity of fatigue is assessed using an 11-point numeric scale, with 0 = no fatigue and 10 = fatigue as bad as you can imagine.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.818","spread":"0.42"},{"groupId":"OG001","value":"-1.005","spread":"2.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.017","spread":"0.37"},{"groupId":"OG001","value":"-0.157","spread":"1.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.191","spread":"0.38"},{"groupId":"OG001","value":"-0.063","spread":"1.93"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol 5-Dimension 5 Level Instrument","description":"EuroQol 5-Dimension 5 Level Instrument (EQ-5D-5L) was not conducted, trial terminated prior to Phase 3. No data collected.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With Cytogenetic Response","description":"Percentage of Participants with Cytogenetic Response with either complete or partial response. Complete cytogenetic response is the disappearance of the chromosomal abnormality without appearance of new ones. Partial cytogenetic response is at least 50% reduction of the chromosomal abnormality.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Hospitalized (Resource Utilization)","description":"Percentage of any participant with a hospitalization admission and discharge date on the same day are counted as a half-day in the duration of hospitalization.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Population Pharmacokinetics (PK): Mean Population Clearance of Galunisertib","description":"Population mean (between-participant coefficient variation \\[CV%\\]) apparent clearance.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":"52"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival is defined as the time from the date of first dose to the date of death from any cause.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"679","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Change in Bone Marrow Fibrosis Grading","description":"Change from baseline in bone marrow fibrosis measured the number of participants with a change in bone marrow fibrosis grading (negative, mild, moderate, and severe).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":41},"commonTop":["Diarrhoea","Asthenia","Vomiting","Pyrexia","Fatigue"]}}}